Navigation Links
Pharmacyclics Announces Interim Results From Two Ongoing Phase 2,Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat,Recurrent Non-Small Cell Lung Cancer

tumor response. The most common severe (Grade 3 or higher) side effects were neutropenia (20.8%), asthenia (16.7%), febrile neutropenia (12.5%), atrial fibrillation (8.3%) and hypotension (8.3%).

"These initial results are encouraging because a relatively low proportion of patients are experiencing disease progression at this time when treated with Xcytrin plus chemotherapy consistent with the synergistic effects we observed in preclinical and early clinical studies," said Richard A. Miller, M.D., president and CEO of Pharmacyclics. "Along with the activity seen in our single agent trial for second-line treatment of non-small cell lung cancer reported last month at ASCO, these data continue to support Xcytrin's potential role in this underserved cancer and further inform the design of our pivotal Phase 3 trial in this indication, which we plan to begin in the first half of 2008."

A New Drug Application for use of Xcytrin in combination with whole brain radiation therapy for treatment of brain metastases from NSCLC was filed with the U.S. Food and Drug Administration in April 2007.

About Non-Small Cell Lung Cancer

The American Cancer Society estimates that there will be more than 213,000 new cases of lung cancer in the United States in 2007. Lung cancer is the leading cause of cancer death, and accounts for over 160,000 deaths in the United States each year. The most common form of lung cancer, non-small cell, is incurable in advanced stages. Lung cancer frequently spreads to other body parts, including the brain.

Xcytrin in Second-Line Lung Cancer

Pharmacyclics is developing Xcytrin as an anti-cancer agent with a novel mechanism of action that is designed to selectively concentrate in tumors and induce apoptosis (programmed cell death). Xcytrin is a redox-active drug that has been shown to disrupt redox-dependent pathways in cells and inhibit oxidative stress-related proteins such as thioredoxin reductase. Its multifunctiona
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Pharmacyclics Announces Promising Results From Phase 2 Clinical Trial of Xcytrin in Recurrent, Metastatic Non-Small Cell Lung Cancer
2. Pharmacyclics Announces Presentations and Published Abstracts on Xcytrin at The 2007 American Society of Clinical Oncology Annual Meeting
3. Pharmacyclics Identifies Functional Biomarkers for its Novel HDAC Inhibitor and Demonstrates Preclinical Anti-Tumor Activity with Brutons Tyrosine Kinase Inhibitors
4. Pharmacyclics Announces Presentations on Its Novel and Selective HDAC and Brutons Tyrosine Kinase Inhibitor Compounds
5. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
6. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
8. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
9. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
Post Your Comments:
(Date:7/10/2014)... 2014   Ventana Medical Systems, Inc.  (Ventana), a ... entered into an agreement with Merck KGaA, Darmstadt, ... in the United States and ... KGaA,s biopharmaceutical division on the development and commercialization of ... Ventana,s proprietary diagnostic assays. In alignment with Merck KGaA,s ...
(Date:7/10/2014)... 10, 2014   LabStyle Innovations Corp . ... announced the appointment of Professor Richard B. ... Board of Directors. Prof. Stone brings ... to LabStyle as an entrepreneur, venture capitalist public, ... governance expert. He currently serves on the board ...
(Date:7/10/2014)... -- Decision Resources Group finds that over half of ... Drug Administration,s (FDA) approval of Vifor Fresenius Medical Care ... by the FDA in November 2013 for the treatment ... dialysis. Other key findings from the report ... : , Bundling: Based ...
Breaking Medicine Technology:Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 3LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 2LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 3LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 4Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 2Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 3
... Study) Results Demonstrate ... of VH(R) IVUS in Drug Development, SAN DIEGO, ... [ESC Booth # A2-D403], a leading manufacturer of,intravascular ultrasound ... of its VH(R) IVUS (Virtual Histology IVUS) in,GlaxoSmithKline,s IBIS-2 ...
... 1 Calabar AB, a privately,held pharmaceutical company ... EUR 350,000 equity financing from the investment company,Karolinska ... a phase II study with repeated dosing. "We ... the minor glands will lead to improved outcomes ...
Cached Medicine Technology:Volcano's VH(R) IVUS Technology Used in Imaging Study of GlaxoSmithKline's Novel Investigational Compound, Darapladib 2Volcano's VH(R) IVUS Technology Used in Imaging Study of GlaxoSmithKline's Novel Investigational Compound, Darapladib 3Volcano's VH(R) IVUS Technology Used in Imaging Study of GlaxoSmithKline's Novel Investigational Compound, Darapladib 4
(Date:7/10/2014)... 10, 2014 One week ahead of ... Safety announced today it will extend compensation benefits to ... wages for workers displaced as a result of factory ... inspections have resulted in the closure of five factories ... cases, raising immediate safety concerns. In May, the Alliance—in ...
(Date:7/10/2014)... NY (PRWEB) July 10, 2014 CBPartners, ... sciences industry, has launched a new website. The ... well as increased access to the firm’s thought pieces, ... provides an ideal platform to showcase our insights, capabilities, ... issues,” says CBPartners’ Chief Executive Officer, Cyrus Chowdhury. ...
(Date:7/10/2014)... (PRWEB) July 10, 2014 A ... program that gets clients off to a great start ... can believe in, has launched a new Eating Disorders ... The new section highlights:, , Different ... Statistic Manual of Mental Disorders (DSM-IV), including anorexia nervosa, ...
(Date:7/10/2014)... A new study from Colorado School of Public ... health remains a major problem in the Navajo Nation ... among Native Americans is abysmal with more than three ... said Terrence Batliner, DDS, MBA, associate director of the ... of Public Health. "The number one problem is access ...
(Date:7/10/2014)... News) -- Most professional football players who have shoulder ... a new study finds. Shoulder instability is a ... return after surgery to fix the problem has been ... included 60 players who had shoulder stabilization surgery. Ninety ... to play, defined as playing in at least one ...
Breaking Medicine News(10 mins):Health News:Alliance for Bangladesh Worker Safety to Double Compensation for Displaced Factory Workers; Members Vote to Extend Wage Benefits from Two to up to Four Months 2Health News:CBPartners Announces New Website 2Health News:Latest A Forever Recovery Launches Eating Disorders Section on Website 2Health News:Study finds widespread oral health problems among Navajo 2Health News:Shoulder Surgery Gets NFL Players Back in the Game 2
... Lee, M.D., breast cancer researcher and assistant member ... grant from General Electric,s $100 million healthymagination Challenge ... genetic makeup to determine if they are predisposed ... GE,s healthymagination grant awarding initiative focuses on "finding ...
... Five Indiana University School of Medicine geriatricians are ... nationwide who will share in $2.5 million in career ... IU School of Medicine was one of the top-funded ... Medicine are: , Tochukwu Iloabuchi, M.D., advanced geriatrics ...
... H. Julia Hannay, the John and Rebecca Moores Professor ... 2012 Ester Farfel Award, a symbol of overall career ... faculty member. The annual award carries a cash prize ... honor recognizing the many roles that we may have ...
... Electrocardiograph (EKG) screening of young athletes can help identify those ... study. Researchers screened nearly more than 1,300 young athletes ... history, family history, a physical exam or prior EKG. Six ... cause sudden cardiac death. The study looked at how ...
... public health threats, early diagnosis of infectious diseases is ... globe where conventional medical tools like microscopes and cytometers ... to make disease screening quicker and simpler. ... or fluid samples are placed. Specific changes in the ...
... of small molecules that kill cancer cells caused by ... both cell and mouse models, demonstrate that the small ... proteins, thus killing the infected tumor cells. The ... issue of the journal Chemistry & Biology . ...
Cached Medicine News:Health News:Moffitt researcher awarded GE grant to develop tool to detect breast cancer metastasis genetic risks 2Health News:Awards to 5 IU School of Medicine physicians address critical need for geriatricians 2Health News:Neuropsychologist receives University of Houston's highest faculty honor 2Health News:Neuropsychologist receives University of Houston's highest faculty honor 3Health News:Heart Test Spots Sudden Death Risk in Young Athletes 2Health News:UCLA researchers combat global disease with a cell phone, Google Maps and a lot of ingenuity 2Health News:UCLA researchers combat global disease with a cell phone, Google Maps and a lot of ingenuity 3Health News:Small molecular bodyguards kill HPV-infected cancer cells by protecting tumor-suppressor 2Health News:Small molecular bodyguards kill HPV-infected cancer cells by protecting tumor-suppressor 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: